Physician profile
Peter J Wolk
NPI 1679561286
$55,616.57
in general payments reported to CMS, 2019-2025
40 companies · $3,274 in 2025
The $3,274 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $4,644 · 2021: $3,762 · 2022: $5,446 · 2023: $3,620 · 2024: $2,979 · 2025: $3,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,873.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $23,357.29 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $10,703.60 | 2019-2020 | |
| Abbott Laboratories | $5,449.53 | 2019-2025 | Aveir, Gallant, Assurity |
| Medtronic, INC. | $2,276.37 | 2021-2025 | Corevalve Evolut R, Micra, Telescope |
| Amgen INC. | $1,963.27 | 2019-2025 | Repatha, Repatha |
| Abiomed | $1,480.42 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $1,465.05 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,093.43 | 2019-2025 | Farxiga |
| Pfizer INC. | $946.90 | 2019-2025 | |
| Edwards Lifesciences Corporation | $639.12 | 2019-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Pascal |
| Merck Sharp & Dohme LLC | $587.14 | 2021-2025 | Verquvo |
| Esperion Therapeutics, INC. | $547.06 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $477.52 | 2019-2022 | |
| Shockwave Medical, INC | $456.33 | 2020-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $422.40 | 2022-2025 | Eliquis, Camzyos |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $416.53 | 2019-2025 | Synergy, Watchman Flx |
| Daiichi Sankyo INC. | $401.09 | 2023-2025 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.74 | 2019-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $335.81 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $309.36 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $246.64 | 2023-2025 | |
| Novo Nordisk INC | $202.01 | 2024-2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $195.06 | 2021-2025 | Onpattro, Amvuttra |
| Portola Pharmaceuticals, LLC | $184.71 | 2019-2020 | |
| Chiesi USA, INC. | $140.08 | 2021-2024 | Kengreal |
| Lexicon Pharmaceuticals, INC. | $130.02 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $126.42 | 2019 | |
| Baxter Healthcare | $111.45 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Lilly USA, LLC | $101.80 | 2023 | Jardiance |
| Philips North America LLC | $97.54 | 2024-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| Heartflow, INC. | $81.48 | 2022-2025 | Ffrct |
| Stryker Corporation | $65.55 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $56.06 | 2021-2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $53.46 | 2021-2023 | Uptravi, Opsumit |
| Arbor Pharmaceuticals, INC. | $35.28 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $30.48 | 2024 | Arcalyst |
| Avinger INC. | $24.12 | 2021 | |
| Biotronik INC. | $22.24 | 2019 | |
| Cardiovascular Systems INC. | $19.46 | 2020-2021 | |
| Biosense Webster, INC. | $16.75 | 2025 | Carto 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Wolk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.